Vectus Biosystems Valuation
Is VBS undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Unter dem Marktwert
Deutlich unter dem Marktwert
Price-To-Sales gegen Gleichaltrige
Price-To-Sales gegen Industrie
PM vs. Fair Ratio
Analysten-Prognose
Share Price vs Fair Value
What is the Fair Price of VBS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Unter dem Marktwert: Unzureichende Daten zur Berechnung des beizulegenden Zeitwerts von VBS für die Bewertungsanalyse.
Deutlich unter dem Marktwert: Unzureichende Daten zur Berechnung des beizulegenden Zeitwerts von VBS für die Bewertungsanalyse.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for VBS?
Other financial metrics that can be useful for relative valuation.
| What is VBS's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | AU$12.77m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 7.5x |
| Enterprise Value/EBITDA | -4.4x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does VBS's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 9x | ||
ATX Amplia Therapeutics | 8.3x | n/a | AU$15.3m |
PAB Patrys | 10.9x | n/a | AU$18.5m |
TRP Tissue Repair | 13.2x | n/a | AU$13.9m |
1AD AdAlta | 3.8x | n/a | AU$13.1m |
VBS Vectus Biosystems | 9x | n/a | AU$12.8m |
Price-To-Sales gegen Gleichaltrige: VBS ist ein guter Wert, wenn man sein Price-To-Sales Verhältnis (9x) mit dem Durchschnitt der anderen Unternehmen (9.1x) vergleicht.
Price to Earnings Ratio vs Industry
How does VBS's PE Ratio compare vs other companies in the AU Biotechs Industry?
Price-To-Sales gegen Industrie: VBS ist aufgrund seines Price-To-Sales Verhältnisses (9x) im Vergleich zum Australian Biotechs Branchendurchschnitt (10.1x) ein guter Wert.
Price to Sales Ratio vs Fair Ratio
What is VBS's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 9x |
| Fair PS Ratio | n/a |
PM vs. Fair Ratio: Unzureichende Daten zur Berechnung der Price-To-Sales Fair Ratio von VBS für die Bewertungsanalyse.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analysten-Prognose: Unzureichende Daten für eine Preisprognose.